Provided by Tiger Trade Technology Pte. Ltd.

Inhibrx Biosciences

112.18
-0.6800-0.60%
Volume:152.26K
Turnover:16.88M
Market Cap:1.65B
PE:-12.64
High:113.95
Open:109.23
Low:107.22
Close:112.86
52wk High:155.29
52wk Low:26.19
Shares:14.67M
Float Shares:8.64M
Volume Ratio:0.45
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.8768
EPS(LYR):-9.0434
ROE:-1773.60%
ROA:-43.61%
PB:-31.07
PE(LYR):-12.40

Loading ...

Inhibrx Biosciences Q2 EPS $(2.34) Beats $(2.39) Estimate

Benzinga Earnings
·
Aug 14

Inhibrx Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 14

Inhibrx Net Loss Widens 27.9% to $36.7 Million in Q2 FY26; Revenue is no Revenue

Reuters
·
Aug 14

Inhibrx Q2 Operating Expenses USD 32.149 Million

THOMSON REUTERS
·
Aug 14

Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile?

Simply Wall St.
·
Jul 23

Inhibrx Shares Fall After Expanding Loan Agreement to $500M

Dow Jones
·
Jul 16

Inhibrx Biosciences Expands Oxford Finance Loan Facility to USD 500 Million

Reuters
·
Jul 16

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

THOMSON REUTERS
·
Jul 16

Inhibrx Biosciences - Second Amendment Adds up to $325 Mln, Including $100 Mln Funded and $225 Mln Available

THOMSON REUTERS
·
Jul 16

Inhibrx Biosciences (INBX) Following Russell Reshuffle With Valuation Still Hard To Pin Down

Simply Wall St.
·
Jul 08

Citizens healthcare analysts hold an analyst/industry conference call

TIPRANKS
·
Jul 08

How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors

Simply Wall St.
·
Jul 03

Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In?

Simply Wall St.
·
Jun 27

Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy

TIPRANKS
·
Jun 16

Inhibrx says FDA accepts ozekibart BLA for conventional chondrosarcoma treatment

Reuters
·
Jun 15

Inhibrx Announces U.S. FDA Acceptance of Bla for Ozekibart in Patients With Conventional Chondrosarcoma

THOMSON REUTERS
·
Jun 15

Inhibrx Biosciences - FDA Sets Pdufa Goal Date of April 14, 2027 for Ozekibart Bla

THOMSON REUTERS
·
Jun 15

Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting

TIPRANKS
·
Jun 04

Inhibrx Biosciences shareholders elect two Class II directors at annual meeting

Reuters
·
Jun 04